The Nasdaq Stock Market opens in less than three hours and Peloton's premarket value is already 7.69% up.
Last session, the Nasdaq Stock Market finished with Peloton rising 3.25% to $144.39. The Nasdaq Stock Market dropped 0.1% to $12,742.50, after two consecutive sessions in a row of losses, on what was a somewhat rough trend trading session.
Peloton's last close was $139.84, 0.33% below its 52-week high of $144.87.
Peloton's Revenue
Year-on-year quarterly revenue growth grew by 232.4%, now sitting on 2.36B for the twelve trailing months.
Previous days news about Peloton
Peloton makes biggest purchase with $420 million precor deal. According to Bloomberg Quint on Mon Dec 21, "Thus far, Peloton's business has focused on sales to consumers, but the company plans to use Precor's relationships to expand into the commercial market.", "The deal will also bring about 100 Precor research-and-development engineers to Peloton. "
Peloton to buy fitness equipment maker precor in $420 million deal. According to MarketWatch on Mon Dec 21, "Precor would function as a Peloton business unit, with current Precor president Rob Barker serving as CEO of the unit as well as general manager of Peloton Commercial.", "Peloton Interactive Inc. plans to acquire a company to help it catch up with all of the exercise bikes and treadmills that customers have been ordering during the pandemic, and investors seemed to like the deal Monday afternoon."
Peloton will spend $420 million to acquire precor, known for making fitness equipment found in hotels, health clubs, and university gyms. According to Business Insider on Mon Dec 21, "The deal is Peloton's largest to date, according to Bloomberg.", "Echelon Fitness, which describes itself as the "most formidable competitor of Peloton," sells bikes cheaper than Peloton's nearly $2,000 model, and reported a sales increase of 700% year-over-year in September."
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
